Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trialsMichał Marczyk, Lajos Pusztai, Anna Mrukwa et al.|Annals of Oncology|2022Cited by 22
Supplementary Figure from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim Blenman, Lajos Pusztai, Michał Marczyk et al.|Unknown|2023Cited by 0
Supplementary Data from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim Blenman, Lajos Pusztai, Bruno V. Sinn et al.|Unknown|2023Cited by 0
Supplementary Data from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim Blenman, Lajos Pusztai, Michał Marczyk et al.|Unknown|2023Cited by 0
Supplementary Figure from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim Blenman, Lajos Pusztai, Michał Marczyk et al.|Unknown|2023Cited by 0